Search

Displaying results 3251 - 3260 of 7502 in total
  1. Drug

    OBE101

    go.drugbank.com/drugs/DB05080
    Experimental

    OBE101 is a new weight loss drug developed by Obecure Ltd. It is a new formulation that is based on the vertigo medication, Betahistine.

  2. Drug

    Midecamycin

    go.drugbank.com/drugs/DB13456
    Investigational

    [A33075] Until 2017, midecamycin was still under the list of approved antimicrobial active pharmaceutical ingredients by Health Canada.[L2791] … In this molecule, an acetoxy group is substituted on the position 9 of the 16-member ring and on position 4 of the terminal sugar.

  3. Drug

    Pimozide

    go.drugbank.com/drugs/DB01100
    Approved

    A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome.

  4. Drug

    Cefotaxime

    go.drugbank.com/drugs/DB00493
    ApprovedInvestigational

    In most cases, it is considered to be equivalent to ceftriaxone in terms of safety and efficacy. Cefotaxime sodium is marketed under various trade names including Claforan (Sanofi-Aventis).

  5. Drug

    BMS-564929

    go.drugbank.com/drugs/DB07286
    Experimental

    So far, it has been developed by Bristol-Myers Squibb for the symptomatic treatment of andropause. … BMS-564929 is an investigational therapeutic agent built to be a selective androgen receptor modulator (SARM).

  6. Drug

    Zilebesiran

    go.drugbank.com/drugs/DB18929
    Investigational

    Zilebesiran is under investigation in clinical trial NCT06272487 (Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care

  7. Drug

    Matrix-M

    go.drugbank.com/drugs/DB16369
    Investigational

    Matrix-M is a saponin-based adjuvant made of nanometer particles, cholesterol, and phospholipid that is developed by Novavax. … [L27981] This compound is administered alongside vaccines to enhance biological functions: creating robust and long-lasting immune responses that may allow for dose-sparing of vaccines.

  8. Drug

    Relatlimab

    go.drugbank.com/drugs/DB14851
    ApprovedInvestigational

    [L41265,L41300] It was the first anti-LAG-3 antibody to demonstrate benefit in a Phase 3 study, as well as the first to receive FDA approval. … efficacy when used alone, drugs like relatlimab have been trialed in combination with other checkpoint inhibitors - for example, PD-1 inhibitors like [nivolumab] or CTLA-4 inhibitors like [ipilimumab] - to

  9. Drug

    Temanogrel

    go.drugbank.com/drugs/DB05227
    Investigational

    APD791 is intended to lower the risk of arterial thrombosis by reducing the amplification of platelet aggregation, arterial constriction and intimal hyperplasia mediated by serotonin. … APD791 is an oral anti-thrombotic drug candidate being evaluated in a Phase 1 clinical trial by Arena.

  10. Drug

    Tubercidin

    go.drugbank.com/drugs/DB03172
    Experimental

    An antibiotic purine ribonucleoside that readily substitutes for adenosine in the biological system, but its incorporation into DNA and RNA has an inhibitory effect on the metabolism of these nucleic acids